CytoMed Therapeutics Company Insiders

CytoMed Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1744) % which means that it has lost $0.1744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2626) %, meaning that it created substantial loss on money invested by shareholders. CytoMed Therapeutics' management efficiency ratios could be used to measure how well CytoMed Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 7, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, CytoMed Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Net Tangible Assets are forecasted to decline to about 485.8 K. As of January 7, 2025, Common Stock Shares Outstanding is expected to decline to about 8.1 M. In addition to that, Net Loss is expected to decline to about (3 M)

CytoMed Therapeutics Workforce Comparison

CytoMed Therapeutics Insider Trading

CytoMed Therapeutics Notable Stakeholders

The success or failure of an entity such as CytoMed Therapeutics often depends on how effective the management is. CytoMed Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CytoMed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CytoMed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of CytoMed Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytoMed Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CytoMed Therapeutics' management manipulating its earnings.

When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.